Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H9NO2 |
Molecular Weight | 151.1629 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=Nc1ccc(cc1)O)O
InChI
InChIKey=RZVAJINKPMORJF-UHFFFAOYSA-N
InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
Molecular Formula | C8H9NO2 |
Molecular Weight | 151.1629 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. Acetaminophen (USAN) or Paracetamol (INN) is a widely used analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. At therapeutic doses, acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, kidney function, or the fetal ductus arteriosus (as NSAIDs can). Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. Acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells, which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works. The antipyretic properties of acetaminophen are likely due to direct effects on the heat-regulating centers of the hypothalamus resulting in peripheral vasodilation, sweating and hence heat dissipation.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=15662292 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5798721E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43 μg × h/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.4 h |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/ Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 2300 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 5300 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
major | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1500 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1900 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 2300 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 3700 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 4000 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 5500 uM] | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. | 1979 Feb 10 |
|
Early metabolic acidosis and coma after acetaminophen ingestion. | 1999 Apr |
|
Severe hypophosphataemia in paracetamol-induced oliguric renal failure. | 1999 Aug |
|
Assay to detect inhibitory substances in serum of patients with acute liver failure. | 1999 Feb |
|
Modifying effects of a mixture of acetaminophen, aspirin, dipyrone and ethenzamide on a multiorgan initiation model and its carcinogenicity in male F344 rats. | 1999 Jan 8 |
|
Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. | 1999 Sep |
|
Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children. | 2000 Apr |
|
[Acetaminophen toxicity in children as a "therapeutic misadventure"]. | 2000 Apr 16 |
|
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. | 2000 Aug |
|
Cerebral edema with herniation during acetaminophen-induced fulminant hepatic failure. | 2000 Jul |
|
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. | 2000 Jun 16 |
|
Deafness associated with abuse of hydrocodone/acetaminophen. | 2000 Jun 27 |
|
Long-chain hydroxydicarboxylic aciduria, carnitine depletion and acetaminophen exposure. | 2000 Mar |
|
Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. | 2000 May |
|
Establishment of a human hepatoma cell line, HLE/2E1, suitable for detection of p450 2E1-related cytotoxicity. | 2000 Oct |
|
Mechanism of action of acetaminophen: is there a cyclooxygenase 3? | 2000 Oct |
|
Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice. | 2000 Oct 15 |
|
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. | 2001 |
|
p-Aminophenol-induced liver toxicity: tentative evidence of a role for acetaminophen. | 2001 |
|
Postoperative analgesia at home after ambulatory hand surgery: a controlled comparison of tramadol, metamizol, and paracetamol. | 2001 Feb |
|
Thermodynamic analysis of compact formation; compaction, unloading, and ejection. II. Mechanical energy (work) and thermal energy (heat) determinations of compact unloading and ejection. | 2001 Feb 1 |
|
Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat. | 2001 Feb 1 |
|
Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. | 2001 Feb 10 |
|
Hemolytic anemia after acetaminophen overdose in patient with glucose-6-phosphate dehydrogenase deficiency. | 2001 Feb 15 |
|
[About paracetamol again]. | 2001 Feb 18 |
|
Separation of cold medicine ingredients by capillary electrophoresis. | 2001 Jan |
|
Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. | 2001 Jan |
|
Gastric emptying in diabetic gastroparetic dogs: ffects of SK-951,a novel prokinetic agent. | 2001 Jan |
|
Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. | 2001 Jan |
|
[Dexketoprofen-trometamol and tramadol in acute lumbago]. | 2001 Jan 11 |
|
Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. | 2001 Jan 26 |
|
Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. | 2001 Mar |
|
Experimental and theoretical microdialysis studies of in situ metabolism. | 2001 Mar |
|
A comparison of ropivacaine and bupivacaine for cervical plexus block. | 2001 Mar |
Patents
Sample Use Guides
2 caplets every 8 hours with water; don't take more than 6 caplets in 24 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10751557
A time- and concentration-dependent decrease in intracellular GSH occurred in freshly isolated type II pneumocytes and alveolar macrophages exposed to subtoxic (= 1 mM) APAP concentrations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:05:34 UTC 2021
by
admin
on
Fri Jun 25 21:05:34 UTC 2021
|
Record UNII |
362O9ITL9D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02AJ17
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
CFR |
21 CFR 341.40
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-VATC |
QN02BE71
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
NCI_THESAURUS |
C2356
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-VATC |
QN02BE01
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ06
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
CFR |
21 CFR 862.3030
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02BE71
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
EPA PESTICIDE CODE |
606318
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-VATC |
QN02BE51
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
LOINC |
75071-1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02BE51
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02BE01
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ13
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
LIVERTOX |
8
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ01
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09611MIG
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
103-90-2
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
1983
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
DB00316
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
PARACETAMOL
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
8055-08-1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
SUPERSEDED | |||
|
Acetaminophen
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
M1317
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | Merck Index | ||
|
ACETAMINOPHEN
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Sparingly soluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R; practically insoluble in ether R. Category: Analgesic; antipyretic. Storage: Paracetamol should be kept in a tightly closed container, protected from light. Definition: Paracetamol contains not less than 98.5% and not more than 101.0% of C8H9NO2, calculated with reference to thedried substance. | ||
|
626
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
203-157-5
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
362O9ITL9D
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
1003009
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | USP-RS | ||
|
CHEMBL112
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
52
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
161
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | RxNorm | ||
|
3001
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
D000082
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
103-90-2
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
5239
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
C198
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE | |||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
PARENT -> METABOLITE ACTIVE |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
PARENT -> METABOLITE ACTIVE |
Metabolite to parent drug I non-uraemic human plasma 0.9-1.6
METABOLITE TO PARENT DRUG RATIO
PLASMA
|
||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE TOXIC -> PARENT |
Metabolite produced hepatic necrosis in man.
AMOUNT EXCRETED
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
IV, LESS THAN 50 Kg |
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
RENAL CLEARANCE |
|
|
||||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||